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THE SYMPTOMATIC, FUNCTIONAL AND QUALITY OF 
LIFE IMPACT OF MULTIPLE SCLEROSIS. REPORT ON A
QUALITATIVE INVESTIGATION OF THE PATIENTS’
PERSPECTIVE
Doward LC1, McKenna SP2, Meads DM2, Kavyasiddhi D2,
Hampson NE2, Mayo KW3
1Galen Research, Manchester, UK; 2Galen Research, Manchester,
Manchester, UK; 3Novartis Pharma AG, Basel, Basel, Switzerland
OBJECTIVES: To determine patients’ views on the impact of
multiple sclerosis (MS) in terms of symptoms experienced,
impact on day-to-day functioning and overall quality of life
(QoL). METHODS: In-depth, unstructured qualitative inter-
views were conducted with MS patients recruited via the MS
Society in the UK. Thematic analysis was conducted on inter-
view transcripts to identify key impact areas. Interpretive phe-
nomenological analysis (IPA) was conducted to explore and
interpret participants’ perceptions of impact; speciﬁcally, the
meaning and importance patients ascribed to areas of impact.
RESULTS: Interviews were conducted with 35 individuals (15
males / 20 females). Patients were aged 31–75 (mean 50; SD
13.2) years with MS duration of 2–58 (mean 17.7; SD 14.2)
years. Eleven (31.4%) had relapsing-remitting MS, 10 (28.6%)
had secondary-progressive, two (5.7%) primary-progressive,
two (5.7%) benign MS and one (2.9%) progressive-relapsing.
MS-type was unknown by nine (25.7%) individuals. Key areas
of symptomatic impact reported were fatigue, pain, incontinence
and mood ﬂuctuation. Impact on memory and broader cognitive
problems were less commonly reported. Key areas of functional
impact related to physical incapacity (difﬁculty/inability walking,
difﬁculty using stairs), problems conducting/completing activities
of daily living, personal care, impact on social functioning,
sexual functioning and work life. IPA analysis revealed that the
most profound effects of symptomatic and functional problems
were experienced in relation to impact on quality of intimate and
social relationships, self-esteem, loss of identity, personal devel-
opment/fulﬁllment and fear of the future. CONCLUSION: The
interviews provided a rich source of information about the
nature of the impact of MS and the concerns of affected indi-
viduals. These data will be used to generate content for new 
MS-speciﬁc patient reported outcome scales of symptoms, 
functioning and quality of life (QoL) suitable for use in clinical
trials.
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SYSTEMATIC REVIEW OF IBANDRONATE FOR
POSTMENOPAUSAL OSTEOPOROSIS
Schnitzer TJ1, Stephenson JJ2, Chen YT3, Sen SS4, Long S2,Abbott T2
1Northwestern University Feinberg School of Medicine, Chicago, IL,
USA; 2Thomson Medstat, Philadelphia, PA, USA; 3Merck & Co., Inc,
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OBJECTIVE: To conduct a systematic review of the effect of
ibandronate on bone mineral density (BMD) and fractures in
postmenopausal women (PMW). METHODS: We followed the
Cochrane collaboration methodology to identify randomized
placebo-controlled trials comparing PMW receiving ibandronate
to those not receiving ibandronate. Trials were included in our
review if they had study duration of ONE year or longer and
reported BMD or fracture incidence as outcomes. A priori
hypotheses dealing with mode and frequency of administration,
dosage, study duration and severity of osteoporosis were devel-
oped to help explain heterogeneity of treatment effects. Hetero-
geneity testing was conducted using regression models. All
analyses were performed using Comprehensive Meta-Analysis,
version 2.2, software. RESULTS: Nine trials met eligibility cri-
teria. The trials included a total of 8784 women; 6111 received
ibandronate and 2673 placebo. Study results were reported at
one, two and three years for ﬁve, two and two studies, respec-
tively. Ibandronate dose and frequency varied across studies and
all trials had > one treatment arm. In all studies, ibandronate
was found to increase BMD in the spine and hip compared to
placebo; the average increase in spine BMD was about 4% and
hip BMD about 2.75%. The BMD increase varied signiﬁcantly
by severity of osteoporosis, mode and frequency of administra-
tion, dosage, and study duration. Only two studies reported data
on fractures. In one study (Chesnut et al, JBMR 2004), iban-
dronate reduced the risk of vertebral fractures but not non-
vertebral fractures compared to placebo after three years of 
treatment. In the other study (Recker et al, Bone 2004), risk
reduction was observed for neither vertebral nor non-vertebral
fractures. CONCLUSIONS: Ibandronate appears to increase
BMD and reduces the incidence of vertebral fractures but not
non-vertebral fractures. Additional data are required to better
assess the impact of ibandronate on BMD and fractures in post-
menopausal osteoporosis.
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CLINICAL EFFICACY AND SAFETY OF BALLOON
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COMPRESSION FRACTURES: A SYSTEMATIC REVIEW OF THE
LITERATURE
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1University of Birmingham, Birmingham, UK; 2Falun Hospital, Falun,
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OBJECTIVES: Balloon kyphoplasty and vertebroplasty are
increasingly used in non-surgical management of patients with
vertebral compression fractures (VCF). To date there has been
no published systematic review that has compared the two 
procedures. METHODS: Number of electronic databases
(MEDLINE, EMBASE and Cochrane Library) were searched
through to March 1, 2004. Citation searching of included studies
and no language restrictions were applied. All controlled and
non-controlled study designs were included. Two reviewers
carried out study selection. RESULTS: Total of 4 comparative
observational studies (3 versus conventional medical manage-
ment [CMM] & 1 versus vertebroplasty) and 13 case series for
balloon kyphoplasty and 2 comparative observational studies (1
study versus kyphoplasty and one study versus CMM) and 57
case series for vertebroplasty were identiﬁed. Across studies,
majority (>80%) of VCF patients were osteoporotic, had expe-
rienced pain for an average of ﬁve to seven months and were
refractory to CMM. Compared to CMM alone, statistically sig-
niﬁcant gains in pain relief and functional improvement were
observed following both balloon kyphoplasty and vertebro-
plasty. Although the magnitude of pain relief appears to be
similar for both procedures, there is consistent evidence of sub-
stantive enhancement in quality of life following balloon kypho-
plasty, evidence that is more limited for vertebroplasty. A total
of 8% and 40% of operated vertebrae experienced cement leak-
ages following balloon kyphoplasty and vertebroplasty, respec-
tively. Unlike balloon kyphoplasty, a number of vertebroplasty
cement leakages are symptomatic (5% of patients) and a number
of serious adverse events have also been reported (e.g. neurologic
injury and pulmonary embolism). CONCLUSION: This review
demonstrates there is level III evidence to support the use of
balloon kyphoplasty and vertebroplasty in the management of
osteoporotic VCFs. Compared to vertebroplasty; balloon kypho-
plasty appears to have a superior safety proﬁle. The results from
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randomised controlled trials are required to inform these 
conclusions.
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RISK FOR OSTEOPOROTIC FRACTURES IS REDUCED IN
PERSISTENT BISPHOSPHONATE USERS
Goettsch WG1, Penning-van Beest FJ1, Erkens JE1, Lynch NO2,
Novak A3, Herings RMC1
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OBJECTIVE: This study aimed to investigate the effect of per-
sistent bisphosphonate usage on the risk for hospitalization due
to osteoporotic fractures. METHODS: The PHARMO database,
which includes linked drug-dispensing records and hospital dis-
charge records of more than one million subjects in deﬁned areas
in The Netherlands, was used to identify new female users of
alendronate, etidronate or risedronate >50 years in the period
January 1996–January 2003. Persistence with bisphosphonate
treatment was determined using the method of Catalan. Within
the cohort a matched case control study was performed. Cases
were selected on the basis of a ﬁrst hospitalization for an osteo-
porotic fracture (index date). Controls were matched 10 :1 to
cases on month of inclusion in the cohort and were assigned a
random index date. The association with risk for fractures was
assessed for bisphosphonate use at the index date and for per-
sistent bisphosphonate use before the index date. RESULTS:
The study cohort included 8,845 new female bisphosphonate
users; 334 women (3.8%) were hospitalized for a fracture after
inclusion in the cohort. A total of 3,280 controls were matched
to the 334 cases. Bisphosphonate use at the index date signiﬁ-
cantly reduced the risk for osteoporotic fractures (RR 0.78;
95%CI 0.61–0.99, adjusted for age, previous fractures and co-
medication). At least one year of persistent bisphosphonate 
usage reduced the risk for osteoporotic fractures even more sub-
stantially (adjusted RR 0.70; 95%CI 0.50–0.99). CONCLU-
SIONS: These results emphasize the importance of persistent
bisphosphonate usage to obtain the maximal protective effect.
Previous studies have demonstrated that persistence with bis-
phosphonates is higher with less frequent dosing regimens but is
still suboptimal. This study has demonstrated that improving
persistence results in reduced hospitalization for osteoporotic
fractures.
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COST-EFFECTIVENESS OF PREVENTION OF
GLUCOCORTICOID-INDUCED OSTEOPOROSIS WITH
ALENDRONATE OR ALFACALCIDOL.THE STOP-STUDY: A
RANDOMIZED PLACEBO-CONTROLLED TRIAL
De Nijs R, Buskens E, Jacobs JW, Bijlsma JWJ on behalf of the
STOP study group
University Medical Center Utrecht, Utrecht,The Netherlands
OBJCETIVE: Glucocorticoids are associated with increased frac-
ture risk. The balance between costs and effects of alendronate
on glucocorticoid-induced osteoporosis (GIOP) was compared to
alfacalcidol and no preventive treatment. METHODS: Cost-
effectiveness analysis with a Markov model to compare 
alendronate and alfacalcidol to placebo based on 5 years of treat-
ment. Lumbar spine bone mineral densities (BMD) of a double
blind randomized controlled trial in patients starting oral GCs
in a daily dosage of 7.5mg prednisone equivalent or higher were
used. Also pooled estimates of the relative risk (RR) of vertebral
fractures from literature were used to estimate fracture incidence.
A discounted iCER threshold of €30.000 per quality-adjusted
life-year (QALY) gained was assumed. RESULTS: Mean age was
60 years. With BMD the iCER in women treated with alen-
dronate was €94.261 per QALY gained an €144.000 in the alfa-
calcidol group. With the pooled RRs in women the iCER were
€58.and €63.115 respectively. Sensitivity analyses applying
pooled RRs to all types of fractures resulted in €29.389 and
€26.457 for women. For men neither treatment reached the
threshold. With BMD as predictor €30.000 was reached at €201
annual costs for alendronate in women and at €78 in men. For
alfacalcidol the threshold prices were €103 in women and €40
in men. With the pooled RRs the threshold price of alendronate
was €300 per year in women and €106 in men. For alfacalcidol
the prices were €218 in women and €72 in men. Sensitivity analy-
sis showed that with treatment duration of 1 year both treat-
ments became cost-effective, presuming persistent beneﬁcial
effect on bone after discontinuation of the drugs. CONCLU-
SIONS: Overall, alendronate and alfacalcidol do not appear
cost-effective in prevention of GIOP in patients with a mean age
of 60 years.
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THE COST-EFFECTIVENESS OF RISENDRONATE COMPARED
TO ALENDRONATE IN POST-MENOPAUSAL WOMEN WITH
ESTABLISHED OSTEOPOROSIS: A POLISH ANALYSIS
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OBJECTIVE: To assess the CE of risendronate vs. alendronate
in post-menopausal women with established osteoporosis.
METHODS: A fracture-incidence based Markov model was
used to perform CEA from a health-care payer perspective, based
on Polish data on health-care resource utilisation and unit cost.
The basic transition probabilities have been taken for published
epidemiological data, where possible from Poland. Efﬁcacy of
treatments in terms of ability to reduce the incidence of hip, ver-
tebral, wrist fractures was populated from the systematic review
and modeled by the use of relative risks in entering a transition
state. Treatments were given for 5 years, assuming that the effect
on fracture probability is instantaneous and persist unchanged
through the treatment period. Separately women at the ages 50,
60, 70, or 80 years of age were analysed. Costs and clinical out-
comes were observed from the time of therapy initiation until
the end of treatment. The effectiveness frontier was mapped and
the cost-effectiveness of each therapy was examined in terms 
of ICER. Extensive sensitivity analyses were undertaken.
RESULTS: At each age-group risendronate was the most effec-
tive and most costly option, giving 17.6; 11.8; 6.5 and 3.08
QALY at 7707.7, 7745.7, 7421.5, and 6117 PLN (1 EURO = 4
PLN) in 50, 60, 70, and 80 aged women, respectively. In the
group at 50 and 70 alendronate was excluded because of
extended dominance and the ICER for risendronate vs. no treat-
ment was 137,651 and 71,084 PLN/QALY, respectively. The
ICER for risendronate vs. alendronate in women at 60 and 80
was 267,393 and 46,732 PLN/QALY, respectively. These ﬁnd-
ings were fairly insensitive to variation in the main parameters.
CONCLUSION: Considering the suggested threshold for cost-
effectiveness, calculated on the basis of 1-year haemodialysis
treatment cost (64,000 PLN) risendronate in comparison to alen-
dronate appears to be cost-effective option in women at 70 and
80.
